A phase 3 study of APN-1607 as a diagnostic agent for Progressive Supranuclear Palsy

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 May 2024 According to a APRINOIA Therapeutics media release, In January 2024 that the U.S. Food and Drug Administration (FDA) granted a ''Study May Proceed'' letter for Aprino's planned Phase 3 study of APN-1607 (florzolotau) in the U.S.,U.K., Europe and Asia.
29 Aug 2023 New trial record
28 Aug 2023 According to a APRINOIA Therapeutics media release, the company plans to file an IND with the FDA in the fourth quarter of 2023 for this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com